6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with Osteoporosis in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Al Khayyat, SG; Baldi, C; Bardelli, M; Cantarini, L; Conticini, E; D'Alessandro, R; Falsetti, P; Frediani, B; Gentileschi, S; Nicosia, A | 1 |
| Bardelli, M; Cantarini, L; Frediani, B; Gaggiano, C; Gentileschi, S; Grosso, S; Maselli, A; Tarsia, M | 1 |
| Baldi, C; Bardelli, M; Cantarini, L; Conticini, E; D'Alessandro, R; Falsetti, P; Frediani, B; Gentileschi, S | 1 |
| Iolascon, G; Moretti, A | 1 |
| Bhardwaj, A; Sinha, NK; Swe, KMM | 1 |
| Amling, M; Barvencik, F; Butscheidt, S; Denecke, J; Jeschke, A; Kubisch, C; Meisler, MH; Neu, A; Oheim, R; Pueschel, K; Rolvien, T; Schinke, T; Yorgan, T | 1 |
| Bhardwaj, A; Osunkwo, I; Sinha, NK; Swe, KM | 1 |
| Celli, M; D'Eufemia, P; Finocchiaro, R; Iacobini, M; Raccio, I; Smacchia, P; Tetti, M; Zambrano, A | 1 |
| Carda, S; Cisari, C; Invernizzi, M; Sainaghi, PP | 1 |
| Baldini, M; Borgna Pignatti, C; Cappellini, MD; D'Ascola, DG; Filosa, A; Forni, GL; Giusti, A; Iolascon, G; Nobili, B; Palummeri, E; Perrotta, S; Pinto, V; Pitrolo, L; Quarta, G; Rigano, P; Rosa, A | 1 |
| La Montagna, G; Malesci, D; Tirri, R; Valentini, G | 1 |
| Anastasi, G; Atteritano, M; Catalano, A; Frisina, N; Gaudio, A; Lasco, A; Melloni, D; Morabito, N; Trifiletti, A | 1 |
| Anastasi, G; Franchina, F; Frisina, N; Galì, A; Gaudio, A; Magno, C; Maisano, D; Melloni, D; Morabito, N | 1 |
| Bifulco, G; Cascella, T; Colao, A; Lombardi, G; Musella, T; Nappi, C; Orio, F; Palomba, S; Tauchmanova, L | 1 |
| Cantatore, FP; Colucci, S; Corrado, A; Grano, M | 1 |
| Benucci, M; Dolenti, S; Manfredi, M; Saviola, G | 1 |
3 review(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Osteoporosis
| Article | Year |
|---|---|
The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.
Topics: Bone Density; Child; Diphosphonates; Humans; Musculoskeletal Pain; Osteoporosis | 2022 |
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Pamidronate | 2023 |
Treatment for osteoporosis in people with ß-thalassaemia.
Topics: Adolescent; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Child; Clodronic Acid; Diphosphonates; Female; Femur Neck; Humans; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Zinc Sulfate | 2016 |
6 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Osteoporosis
| Article | Year |
|---|---|
Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.
Topics: Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Follow-Up Studies; Humans; Male; Osteoporosis; Taurine; Time Factors; Young Adult | 2010 |
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
Topics: Adolescent; Adult; Alkaline Phosphatase; Back Pain; beta-Thalassemia; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Diphosphonates; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Quality of Life; Treatment Outcome; Young Adult | 2012 |
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate | 2004 |
Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Anilides; Biomarkers; Bone Density; Calcium; Chromatography, High Pressure Liquid; Diphosphonates; Drug Therapy, Combination; Estradiol; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Nitriles; Osteoporosis; Parathyroid Hormone; Phosphorus; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome; Vitamin D | 2005 |
Effects of neridronate treatment in elderly women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Diphosphonates; Female; Humans; Male; Osteoporosis; Pilot Projects; Quality of Life | 2005 |
[Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate].
Topics: Aged; Arthritis, Rheumatoid; Bone Resorption; Calcium; Data Interpretation, Statistical; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Osteoporosis; Polymyalgia Rheumatica; Sjogren's Syndrome; Time Factors; Treatment Outcome; Vitamin D | 2006 |
7 other study(ies) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Osteoporosis
| Article | Year |
|---|---|
Efficacy of intravenous neridronate in transient osteoporosis of the hip.
Topics: Acute Disease; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoporosis; Pain; Retrospective Studies | 2022 |
Neridronate for transient osteoporosis of the hip in a child.
Topics: Child; Diphosphonates; Female; Hip Joint; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Osteoporosis; Pregnancy; Quality of Life | 2022 |
Intravenous neridronate is effective in regional migratory osteoporosis.
Topics: Diphosphonates; Humans; Osteoporosis | 2022 |
Severe bone loss and multiple fractures in SCN8A-related epileptic encephalopathy.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Child; Diphosphonates; Female; Fractures, Multiple; Humans; Infant; Mice; Mice, Knockout; Mutation; NAV1.6 Voltage-Gated Sodium Channel; Osteoporosis; Spasms, Infantile | 2017 |
Acute pseudogout following intravenous neridronate for osteoporosis.
Topics: Acute Disease; Aged, 80 and over; Chondrocalcinosis; Diphosphonates; Female; Humans; Osteoporosis | 2010 |
Successful neridronate therapy in transient osteoporosis of the hip.
Topics: Adult; Arthrography; Diphosphonates; Female; Follow-Up Studies; Hip Joint; Humans; Injections, Intramuscular; Magnetic Resonance Imaging; Osteoporosis; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.
Topics: Adult; Aged; Cells, Cultured; Cholecalciferol; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteocalcin; Osteoporosis | 2005 |